Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hVEGF26-104/RFASE in advanced solid tumors
NCT02237638Phase 1Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Apr 2014
- Primary completion
- Jan 2020
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hVEGF26-104 + RFASE in solid tumor, sponsored by Amsterdam University Medical Center. Primary endpoints: Adverse Events, Neutralization of endogenous VEGF in serum and 1 more. Started Apr 2014; status: completed.
02
Drugs
hVEGF26-104 + RFASE
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02237638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02237638.